BioMelbourne Network
Progressing BioIndustry

News and Opinions

Previous1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9

2015

May

New Awards Recognise Women in Leadership in Biotech, Medtech and Healthcare Technology

22 May 2015.  Australian women do comparatively well in biotechnology, medtech and health care technology – with 11.1% of companies in the sector in the ASX 200 having female executive key management personnel and 11.9% in the ASX 500.However, in recognition that these figures need to improve and to honor outstanding women in the sector, The BioMelbourne Network will, this Friday, announce its ... read more…

dorsaVi Secures London Underground and VINCI Construction as its First UK Occupational Health and Safety Customers

21 May 2015.  Medical device company dorsaVi Ltd (ASX: DVL) today announced the signing of its first two UK-based occupational health and safety (OHS) customers: London Underground and VINCI Construction UK Ltd. The agreements with the two industry leaders represent a major milestone for the Australian company who formally introduced its innovative OHS technology, ViSafe™, into the UK market in... read more…

Starpharma - Spare Lab/Office Space

21 May 2015.  Starpharma has some surplus lab and office space at their new premises in Abbotsford. Good lab space is certainly hard to find so hopefully it would be of benefit to all of you. Read the brochure below for more details: read more…

Gordagen Wins High Court of Malaysia Judgement for Breach of Confidentiality

20 May 2015.  Gordagen Pharmaceuticals Pty. Ltd., a private Australian company commercialising evidence-based dietary supplements and pharmaceuticals, today announced that the High Court of Malaysia has issued a judgement against Ms. Nurul Athirah binti Sufi (Ms. Athirah), a former employee of the Company. Ms. Athirah was represented to Gordagen in January 2014, as a chartered accountant with a... read more…

INV102 (Oral Nadolol) Data Presented to American Thoracic Society Meeting in Denver, Colorado

19 May 2015.  Australian respiratory technology company Invion Limited (ASX: IVX) has presented data from a trial of lead compound INV102 (oral nadolol) to international medical experts at a prestigious US pulmonary conference.Trial investigators have shown delegates at the American Thoracic Society (ATS) meeting that an ongoing Phase 2 study of Invion’s INV102 as an aid to smoking cessation ha... read more…

Your invitation to the Industry Growth Centre Consultations for the Medical Technologies and Pharmaceuticals Sector

18 May 2015.  Dr Bronwyn Evans, Chair of the Medical Technologies and Pharmaceuticals Industry Growth Centre would like to invite you to participate in a range of consultations designed to shape the future of the sector. Dr Evans has scheduled a range of opportunities for interested participants to share their views about how the productivity and competitiveness of the sector can be significan... read more…

Australia’s Minister for Industry and Science Declares Trajan is “Leading the Way” in World Class, Australian-Based Advanced Manufacturing

15 May 2015.  Pioneering collaboration and world-class products meeting global standards – these were the take-home impressions of the Australian Minister for Industry and Science, Ian Macfarlane, during a special visit to Trajan Scientific and Medical (Trajan) global headquarters facilitated by Mr Michael Sukkar, Federal Member for Deakin, Victoria.Trajan exports 98 per cent of its products th... read more…

Phosphagenics: Oxymorphone Patch Program Update

14 May 2015.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), has completed a review of its TPM®/Oxymorphone patch development program using specialist external consultants. On the back of previously announced clinical trial results showing that the TPM®/Oxymorphone patch can deliver blood levels of oxymorphone corresponding to the therapeutic levels seen with ... read more…

Sun Biomedical Limited to Aquire Dimerix Bioscience

13 May 2015.   The Board of Sun Biomedical Ltd, an Australian biotechnology company, is pleased to announce that the Company has signed an implementation agreement to acquire 100% of Dimerix Bioscience Ltd (Dimerix), a public unlisted clinical stage drug discovery and development company, based in Melbourne. Dimerix’s lead clinical program is a Phase 2 study in patients with Chronic K... read more…

Nexvet Appoints Dr. Jurgen Horn as Chief Product Development Officer

11 May 2015.  Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role at Nexvet in August 2015. Dr. Horn most recently served as Senior Director of Global Innovation Strategy at Elanco, one of the wor... read more…